Preventing cognitive decline in preclinical Alzheimer’s disease

Wim J Riedel1,2,3

Alzheimer’s disease (AD) is a chronic neurodegenerative disease leading to cognitive decline, dementia, and ultimately death. Despite extensive R&D efforts, there are no diseases modifying treatments for AD available. The stage in which patients receive a clinical diagnosis of probable AD may be too late for disease modifying pharmacotherapy. Prevention strategies may be required to successfully tackle AD. Preclinical AD applies to over half of all healthy elderly subjects and manifests by signs of amyloid deposition and/or neuronal injury in the brain, preceding the stage in which symptoms of dementia, cognitive and functional impairment become observable. Prevention trials in preclinical AD require longer and larger clinical trials using biomarkers and cognitive endpoints, which requires collaboration across academia, government and industry.

Addresses
1 Cambridge Cognition Ltd., Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge CB5 9TU, UK
2 Faculty of Psychology & Neurosciences, Maastricht University, The Netherlands
3 Department of Psychiatry, University of Cambridge, Cambridge, UK

Corresponding authors: Riedel, Wim J (wim.riedel@camcog.com, w.riedel@maastrichtuniversity.nl)

Introduction

Alzheimer’s disease (AD) is the most common neurodegenerative condition. Currently 35 million patients suffer from AD and this number is estimated to rise to 115 million patients worldwide by 2050 [1,2]. At microscopic level, AD is characterized by the presence of large numbers of neuritic plaques, neurofibrillary tangles and by neuronal cell loss beginning in the hippocampus [3]. Clinically AD manifests itself by progressive decline of memory and other cognitive functions. Mild cognitive impairment (MCI) is considered to reflect a transitional stage between normal aging and dementia [4].

Recently, an asymptomatic phase, preclinical AD, has been defined as the stage preceding MCI and AD [5,6]. Subjects in the preclinical stage are at risk for AD, as shown by biomarkers signaling amyloid deposition in the brain (low amyloid-beta in cerebrospinal fluid [CSF] or increased binding to amyloid ligands in positron emission tomography [PET]) and signs of neuronal injury, such as high tau or phospho-tau in CSF, as well as signs of cortical thinning and hippocampal atrophy on structural magnetic resonance imaging (MRI) [7].

At present, five stages describe the potential recognition of approx. 96% of all healthy older adults (>65 years) 54% of whom are at risk developing AD before they express MCI, based on assessment of amyloid accumulation in the brain in the first stage, signs of neuronal injury in the second stage and subtle cognitive impairment in the third stage [9**] (see Table 1).

Preclinical Alzheimers disease

The categorization of preclinical AD is based on new research criteria commissioned by the National Institute on Aging and the Alzheimer’s Association (NIA-AA), which distinguish three advancing stages (1–3) of preclinical AD from normality (stage 0) [6] in addition to the description of Suspected Non-AD Pathophysiology (SNAP) and a remaining unclassified category [9**]. SNAP is defined by presence of neuronal injury markers and absence of amyloid with or without signs of cognitive impairment. The unclassified category is defined by presence of subtle cognitive impairment and absence of amyloid with or without markers of neuronal injury. The stages at which cognitive and behavioral symptoms become manifest, are MCI and probable AD. The latter represents what is known in NINCDS ADRDA as clinical diagnosis of probable AD. Prodromal MCI is defined as clinically abnormal performance on tests of episodic memory along with evidence of amyloid deposition in the brain [11].

Vos et al. [10**] describe a longitudinal study carried out at the Knight Alzheimer’s Disease Research Center (KADRC) at Washington University in St. Louis, Missouri, of 311 cognitively normal elderly people. Participants were older than 65 and had a Clinical Dementia Rating (CDR) of 0 at baseline, indicating normal cognition. Amyloid pathology and neurodegeneration were assessed from CSF, measured by amyloid-beta and tau, respectively. The results of classification into stages of preclinical AD was very similar to that reported by the Mayo Clinic Study of Aging (MCSA) in a separate population of cognitively healthy older adults using amyloid imaging. The average of these classifications are shown in Table 1. These studies show that preclinical AD is common and can be diagnosed by markers in CSF [9**,10**]. A strong association was shown between
Clinical trials before Alzheimer's disease

In the past decades, clinical drug trials have been carried out in patients with mild to moderate AD and this has only yielded the currently registered drugs, the cholinesterase inhibitors and an NMDA blocker, which act at best symptomatic, that is, they temporarily stop or attenuate decline but do not halt it. Since recently, clinical trials of disease modifying agents are currently being carried out in prodromal AD. Although no clinical trials are known to date to be carried out in preclinical AD, the door to this has been opened by a recent new Food and Drug Administration (FDA) guidance on developing drugs for treatment of preclinical AD [13]. The possibility of clinical drug trials is suggested in subjects with only subtle cognitive deficits in the absence of any detectable functional impairment. An effect on a valid and reliable cognitive assessment used as a single primary efficacy measure would be considered for approval by FDA [14]. In relation to the staging descriptions above, this applies to subjects in preclinical AD, in whom cognitive decline would be prevented. Decline can also be described as poor performance on more challenging cognitive tests [6]. The preclinical criteria emphasize memory. However, declines in other domains may be the initial cognitive signal of impending AD [15,16].

Cognitive assessments

The instrument hitherto most used to assess changes in cognition in trials in mild to moderate AD is the Cognitive subscale of the Alzheimers Disease Assessment Scale, or ADAS-Cog [17]. However, due to a restriction of range in test scores (ceiling-effect), it lacks sensitivity to detect changes in earlier stages such as MCI and preclinical AD [18]. The Clinical Dementia Rating scale, in particular its so-called Sum of Boxes score (CDR-SB), has been proposed as primary assessment instrument in prodromal AD [19]. However, because of its expected value of zero in preclinical AD, CDR-SB is not expected to be targeting cognitive performance in that range. The studies in preclinical AD described here in the MCSA cohort [9] and in the KADRC cohort [10], have used neuropsychological test batteries to detect signs of subtle cognitive impairment in stage 3 of preclinical AD. In both studies detection was set at scores below the 10th percentile, which resembled an approx. 1.25 SD deviation from reference values in normal controls. In the MCSA study a global composite cognitive score comprising the executive, language, visuospatial and memory domains, was used after it was established that a similar result would be obtained when using a memory domain score [9]. In the KADRC study an episodic memory composite score was used as the measure of cognition to define stage 3 of preclinical AD [10].

Cognition and amyloid

Although previous studies had observed only moderate negative relationships between amyloid-beta and cognition and/or episodic memory, a recent meta-analysis established a modest significant relationship between amyloid-beta and cognition [20]. In the Australian Imaging, Biomarker and Lifestyle (AIBL) study, more decline was reported in preclinical AD subjects with high amyloid-beta after 18 months on memory and language (fluency) and similar memory decline was also seen in individuals genetically at risk as determined by presence of a ApoE4 allele(s) [21,22]. These studies suggest that in preclinical AD, elevated amyloid-beta load is associated with subtle AD-related cognitive impairment. It was also concluded that the relationship between amyloid-beta and cognitive decline in preclinical AD may be best understood from prospective studies [21]. Data from prospective studies suggest that high amyloid-beta does increase the risk of progression to MCI [23], and that
subtle decline in episodic memory, even in the absence of any change in clinical status, can be detected within 18 months [24].

Cognitive diagnostic screening instruments
Neuropsychological tests can facilitate the detection of subtle signs of cognitive impairment. Episodic memory tests have been shown effective to detect MCI and differentiate from AD [25**]. Because in preclinical AD, subjects are functioning cognitively normal and at most show some subtle deficits, new technologies hold promise for wide-scale application in both detection as well as monitoring progression. Web-based testing shows promise in this respect and attempts for validation of web-based cognitive assessments are already undertaken in various contexts [26**,27,28]. Although the unsupervised nature may introduce some new methodological challenges, the obvious advantages are, for example, firstly, increasing reliability by taking advantage of more frequent assessments and hence averaging out the occasional 'bad day' and finally, creating time for cognitive assessment rather than scheduling it at the end of an exhaustive hospital visit including blood and CSF sampling, MRI scanning, PET scanning, etc.

Enabling early detection and intervention in (preclinical) AD: need for public–private collaborative research
In clinical practice dementia diagnosis rates are low; less than half of people in the UK living with dementia actually receive a dementia diagnosis [29]. There is a need for diagnostic procedures in mainstream healthcare otherwise we develop treatments for early phase disease but the patients will not be identified. Timely diagnosis and intervention will have a positive impact on healthcare system resources, with or without disease modifying treatments [30*]. However, trials may require thousands of patients and several years of observation. The scientific challenges range from identifying subjects at risk, clinical endpoints and biomarkers, and establish how to achieve prevention. A public–private collaborative approach may be required to enable efficient design and execution of clinical AD prevention trials. In the US, since 2005 the longitudinal Alzheimer's Disease Neuroimaging Initiative (ADNI) has been validating the use of biomarkers and imaging for AD clinical trials and diagnosis [31]. In Australia, there is the AIBL study [32]. Within the European Union (EU), there is the DESCRIPA study on early AD diagnosis [33] and also the Innovative Medicine Initiative (IMI) consortia, such as the European Medical Information Framework (EMIF). One of IMI-EMIF’s goals is to establish and qualify early biomarkers of AD that might be beneficial in early intervention trials. A new proposed consortium will be the European Platform to facilitate Proof of Concept trials to enable prevention in AD (IMI EPOC). It aims to build registries of subjects at risk of AD, to invite subjects to join a longitudinal natural history study to qualify and validate AD biomarkers and to invite a subset of these subjects to participate in a pharmacological intervention trial.

Conclusions
Preclinical AD is an important clinical category, which applies to more than half of the normal elderly population over 65 years of age. It is hoped that new disease modifying therapies will allow AD prevention trials. Novel pharmacological treatments now attempt to target beta amyloid production, tau aggregation and nerve regeneration. It is hoped that such treatments can have an impact on the underlying neurodegeneration of AD very early, or even before its onset [34], in preclinical AD. Clinical pharmacology safety studies such as the single and multiple ascending dose studies will remain the starting point in drug development, yet will probably move swiftly into an adaptive trial scheme [35,36]. Although it may be more difficult to implement an adaptive trial for AD than for breast cancer, unblinded adaptive trials like the I-SPY 2 [37] will be much more attractive for patients. However, initially blindling will almost certainly be required in a preventive AD trial. Even though biomarker cut-points to characterize subgroups such as stages 1–3 in preclinical and prodromal AD stages have been described, these are not yet considered mainstream and also, placebo effects cannot be ruled out [38]. An adaptive trial design requires fast readouts so that treatment regimens can be adjusted during the trial; this will present a challenge for biomarkers or cognitive measures to provide early evidence of a treatment effect. The trajectory from preclinical AD to AD demands different types of markers at different stages. PET imaging of amyloid and CSF sampling of Aβ yield biomarkers for stratification, yet their invasiveness and cost are limiting factors. Instead, non-invasive diagnostic markers — such as a blood-based biomarker — are highly desired [38]. Future trials could employ longitudinally validated web-based computerized cognitive tests as essential element of an evidence-based diagnosis of AD in the trajectory from preclinical AD to prodromal AD to probable AD. Attempts to build a large registry of volunteers have already started (e.g., see http://www.nia.nih.gov/alzheimers/features/new-alzheimers-prevention-registry-recruiting-250000-volunteers and http://www.endalznow.org). Cardinal elements of a registry would be repeated cognitive assessments over a longer period of time in combination with biomarker assessments of amyloid and tau.

References and recommended reading
Papers of particular interest, published within the period of review, have been highlighted as:

* of special interest
** of outstanding interest


A cross-sectional evaluation of the NIA-AA criteria for preclinical AD indicates that the 1-3 staging criteria of preclinical AD coupled with stage 0 and SNAP categories classify 97% of cognitively normal subjects from a population-based sample, leaving only 3% unclassified.


Preclinical AD is common in cognitively normal elderly people and is associated with future cognitive decline and mortality. Compared with individuals classed as normal, participants with preclinical AD had an increased risk of death after adjusting for covariates.


C-DIR-SB assesses cognitive impairment and is derived from ratings in six cognitive and functional domains, or boxes (memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care). C-DIR-SB is the total score of all separate boxes (range 0-18, with 0 as best score).


In 44 healthy older adults enrolled in the Australian Imaging, Biomarkers and Lifestyle Rate of Change SubStudy, high amyloid-beta was associated with greater decline in episodic memory measures over 6 months.


CANTAB paired associate learning (PAL) and CERAD Wordlist Learning delayed Recall could differentiate between normal aging, aMCI and AD, such that 84.5% of the cases were correctly classified. These results showed that CANTAB can be used for screening of AD—typical memory impairment.


In general intelligence, the higher-order factor g is accounted for by cognitive tasks co-recruiting multiple brain networks. Intelligence is an emergent property of three anatomically distinct cognitive domains (short-term memory, reasoning and verbal processing), each of which has its own capacity.


Although early diagnostic assessment and treatment has significant up-front costs, identifying AD patients at an early stage results in cost savings and health benefits compared with no treatment or treatment in the absence of early assessment.


